Utility of Assessing CD3 Cell Chimerism Within the First Months After Allogeneic Hematopoietic Stem-cell Transplantation for Acute Myeloid Leukemia

Overview

Journal HLA

Date 2022 Jan 22

PMID 35064642

Authors

Mehdi Bendjelloul

Cedric Usureau

Pascaline Etancelin

Zuzana Saidak

Delphine Lebon

Loic Garcon

Jean-Pierre Marolleau

Judith Desoutter

Nicolas Guillaume

Affiliations

Soon will be listed here.

Abstract

After allogeneic hematopoietic stem-cell transplantation (alloHSCT), the chimerism assay is used to monitor cell engraftment and quantify the respective proportions of donor/recipient cells in blood or bone-marrow samples. Here, we aimed to better assess the utility of determining CD3 cell chimerism within the first 6 months post alloHSCT. One hundred and thirty five patients diagnosed with acute myeloid leukemia were enrolled in this study. We observed significantly lower overall survival and relapse free survival for patients without full donor chimerism (<95%, <98%, <99%) in whole blood at Day 30, as well as at Day 90 after alloHSCT, than for patients with full donor chimerism. This outcome was not observed when assessing selected CD3 cells. However, at Day 90, patients with discordant whole blood versus selected CD3 cell chimerism showed both significantly lower overall survival and relapse free survival, giving an interest to assess selected cells chimerism.

Citing Articles

Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies.

Puzo C, Seropian S, Rinder H, Tormey C, Siddon A Bone Marrow Transplant. 2025; .

PMID: 39806028 DOI: 10.1038/s41409-025-02510-8.

The predictive value of T-cell chimerism for disease relapse after allogeneic hematopoietic stem cell transplantation.

Li Z, Wang J, Deng L, Liu X, Kong F, Zhao Y Front Immunol. 2024; 15:1382099.

PMID: 38665912 PMC: 11043518. DOI: 10.3389/fimmu.2024.1382099.

Can novel methods replace the gold standard chimerism method after allogeneic hematopoietic stem cell transplantation?.

Abatay Sel F, Savran Oguz F Ann Hematol. 2023; 103(4):1035-1047.

PMID: 37801085 DOI: 10.1007/s00277-023-05448-3.

Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia.

Malagola M, Polverelli N, Beghin A, Bolda F, Comini M, Farina M Front Oncol. 2023; 13:1133418.

PMID: 36950550 PMC: 10025489. DOI: 10.3389/fonc.2023.1133418.

Utility of assessing CD3 cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia.

Bendjelloul M, Usureau C, Etancelin P, Saidak Z, Lebon D, Garcon L HLA. 2022; 100(1):18-23.

PMID: 35064642 PMC: 9303291. DOI: 10.1111/tan.14557.

References

Desoutter J, Usureau C, Jacob V, Lebon D, Caulier A, Da Costa C . A one-step assay for sorted CD3 cell purity and chimerism after hematopoietic stem cell transplantation. HLA. 2020; 97(3):183-187. DOI: 10.1111/tan.14168. View

Koreth J, Kim H, Nikiforow S, Milford E, Armand P, Cutler C . Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014; 20(10):1516-21. PMC: 4477288. DOI: 10.1016/j.bbmt.2014.05.025. View

Rosenow F, Berkemeier A, Krug U, Muller-Tidow C, Gerss J, Silling G . CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant. 2013; 48(8):1070-6. DOI: 10.1038/bmt.2013.2. View

Bendjelloul M, Usureau C, Etancelin P, Saidak Z, Lebon D, Garcon L . Utility of assessing CD3 cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia. HLA. 2022; 100(1):18-23. PMC: 9303291. DOI: 10.1111/tan.14557. View

Hanson V, Adams B, Lord J, Barker A, Poulton K, Lee H . Assessment of the purity of isolated cell populations for lineage-specific chimerism monitoring post haematopoietic stem cell transplantation. Tissue Antigens. 2014; 82(4):269-75. DOI: 10.1111/tan.12172. View

Vives J, Casademont-Roca A, Martorell L, Nogues N . Beyond chimerism analysis: methods for tracking a new generation of cell-based medicines. Bone Marrow Transplant. 2020; 55(7):1229-1239. DOI: 10.1038/s41409-020-0822-8. View

Breuer S, Preuner S, Fritsch G, Daxberger H, Koenig M, Poetschger U . Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia. 2011; 26(3):509-19. DOI: 10.1038/leu.2011.244. View

Lee H, Saliba R, Rondon G, Chen J, Charafeddine Y, Medeiros L . Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2015; 21(11):1948-54. PMC: 4604040. DOI: 10.1016/j.bbmt.2015.07.005. View

Kharfan-Dabaja M, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R . Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and.... Transplant Cell Ther. 2021; 27(8):642-649. DOI: 10.1016/j.jtct.2021.04.007. View

10.

Blouin A, Ye F, Williams J, Askar M . A practical guide to chimerism analysis: Review of the literature and testing practices worldwide. Hum Immunol. 2021; 82(11):838-849. PMC: 9492519. DOI: 10.1016/j.humimm.2021.07.013. View

11.

Mellgren K, Arvidson J, Toporski J, Winiarski J . Chimerism analysis in clinical practice and its relevance for the detection of graft rejection and malignant relapse in pediatric hematopoietic stem cell transplant patients. Pediatr Transplant. 2015; 19(7):758-66. DOI: 10.1111/petr.12580. View

12.

Dubois V, Alizadeh M, Bourhis J, Etancelin P, Farchi O, Ferrand C . [Chimerism analysis after hematopoietic cell transplantation: Guidelines from the Francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]. Bull Cancer. 2017; 104(12S):S59-S64. DOI: 10.1016/j.bulcan.2017.08.010. View

13.

Rupa-Matysek J, Lewandowski K, Nowak W, Sawinski K, Gil L, Komarnicki M . Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. Transplant Proc. 2011; 43(5):1915-23. DOI: 10.1016/j.transproceed.2011.02.011. View